If you're familiar with the writings of former New York Times journalist Melody Petersen, you might know that she released a damning examination of the pharmaceutical industry in 2008 entitled "Our Daily Meds". I'm currently reading the book, and like many of the reviewers at Amazon.com I'm absolutely in agreement with her simple thesis that drug company marketing bears much of the responsibility for America's addiction to prescription drugs.

Two-thirds of Americans take some sort of prescribed pill, spending more each year than 13 countries combined, including Canada, Great Britain and Japan. Over a 24-year period from 1980 to 2003, annual spending for prescriptions went from $12 billion to $197 billion. It's no wonder pharmaceutical companies aren't inventing drugs as rapidly as they once did. Just like the movie industry, it's easier to release a second, third and fourth version of a proven formula than to introduce drugs without an existing fan base.

IN PICTURES: Top 10 Forex Trading Rules

Five Best Sellers
The top-five drugs in terms of global sales are Lipitor, Plavix, Nexium, Seretide and Enbrel. Combined, their revenues in 2008 were $43.5 billion, which would rank these drug makers as 77th in gross domestic product if they formed a country. Although I've included a table with the total sales of the companies that make these best sellers, I thought it would be more interesting to uncover five companies with best-selling drugs that generate more than 50% of their sales from just one product. With many major drugs' patent protection expiring in the next five years, those overly dependent on one drug are bound to take a hit. Frankly, I wouldn't feel too sorry for them. After all, what goes up must come down.

Top-Five prescription Drugs Globally 2008

Company Sales - Leading Drug Total Revenues Percentage of Total Market Cap
Pfizer (NYSE:PFE) $13.66B - Lipitor $43.4B 31.5% $111.07B
Bristol Myers Squibb (NYSE:BMY) & Sanofi-Aventis (NYSE:SNY) $8.63B - Plavix $20.6B/35.6B

15.4%

$41.87B/$86.03B
Astra Zeneca (NYSE:AZN) $7.85B - Nexium $32.5B 24.2% $67.74B
GlakoSmithKline (NYSE:GSK) $7.70B - Seretide $36.5B 21.1% $97.49B
Amgen (Nasdaq:AMGN) & Wyeth (NYSE:WYE) $5.70B - Enbrel $15.8B/$15.7B 18.1% $51.60B/$63.12B
Source: IMS Health. Figures are in U.S. dollars.


Diversification Protects Investors
None of the above companies relies too heavily on its wonder drug. Their investors should be happy about this. Even Pfizer, with its industry-leading Lipitor, doesn't push the envelope. I'm sure Melody Petersen would have some explanation for this. I tend to think these companies are doing a better job diversifying than she might give them credit for. From a business perspective, I have to believe they're spending more time and money figuring out what will replace these home-run drugs than detractors realize. Sure, the past few years haven't been as lucrative as in previous decades, but these companies have still made gobs of money. That's all investors can ask for. (Learn how to use revenue and expenses, among other factors, to break down and analyze a company. See Understanding The Income Statement.)

When I run down IMS Health's (NYSE:IMS) list of the top 15 drugs worldwide, I'm interested in one or two companies that have leveraged their futures on a one-hit wonder. I'd avoid those right now. Genentech, maker of cancer drug Avastin, had $4 billion in sales in 2008, ranking it 15th. As an independent company, Avastin's revenues accounted for 40% of its product sales, but that's stretching it. Add in its royalty revenue and Avastin's contribution is more like 30%, similar to Pfizer's. In March 2009, Roche Holdings bought Genentech for $95 per share. As a Roche subsidiary, it contributes approximately 10% to the top line. Therefore, it's out.

After checking all 10 drugs outside the top five listed above, the only company that comes close is Wyeth, maker of Zyprexa, a drug used to help those who suffer from bipolar disorder. Its 2008, sales were $5 billion, 31.8% of its total revenue. Between Zyprexa and Enbrel, you might have a problem. At least that would be the case if Pfizer weren't buying Wyeth for $68 billion. It seems Pfizer needed a few more products to protect it from Lipitor's expiring patent protection. (Learn how to find a healthy pharmaceutical investment in a market full of weak drugs in Measuring The Medicine Makers.)

Bottom Line
Consolidation continues in the pharmaceutical industry. If you're an investor in one of these behemoths, you've got to be happy - unless you're an advocate of science-driven healthcare companies like Melody Petersen.

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

Related Articles
  1. Investing News

    What You Can Learn from Carl Icahn's Mistakes

    Carl Icahn has been a stellar performer in the investment world for decades, but following his lead these days could be dangerous.
  2. Options & Futures

    What Does Quadruple Witching Mean?

    In a financial context, quadruple witching refers to the day on which contracts for stock index futures, index options, and single stock futures expire.
  3. Charts & Patterns

    How To Use Volume To Improve Your Trading

    The basic guidelines to analyzing volume may not apply in all situations, but overall, they can help direct entry and exit decisions.
  4. Options & Futures

    4 Equity Derivatives And How They Work

    Equity derivatives offer retail investors opportunities to benefit from an underlying security without owning the security itself.
  5. Trading Strategies

    4 Common Active Trading Strategies

    Active trading entails buying and selling securities with the intent of profiting from short-term price movements.
  6. Stock Analysis

    Analyzing Altria's Return on Equity (ROE) (MO)

    Learn about Altria Group's return on equity (ROE) and analyze net profit margin, asset turnover and financial leverage to determine what is causing its high ROE.
  7. Investing News

    Icahn's Bet on Cheniere Energy: Should You Follow?

    Investing legend Carl Icahn continues to lose money on Cheniere Energy, but he's increasing his stake. Should you follow his lead?
  8. Stock Analysis

    Analyzing Google's Return on Equity (ROE) (GOOGL)

    Learn about Alphabet's return on equity. How has its ROE changed over time, how does it compare to its peers and what factors are driving ROE for the company?
  9. Investing News

    Is Buffett's Bet on Oil Right for You? (XOM, PSX)

    Oil stocks are getting trounced, but Warren Buffett still likes one of them. Should you follow the leader?
  10. Options & Futures

    Five Advantages of Futures Over Options

    Futures have a number of advantages over options such as fixed upfront trading costs, lack of time decay and liquidity.
RELATED FAQS
  1. What is a derivative?

    A derivative is a contract between two or more parties whose value is based on an agreed-upon underlying financial asset, ... Read Full Answer >>
  2. Do hedge funds invest in commodities?

    There are several hedge funds that invest in commodities. Many hedge funds have broad macroeconomic strategies and invest ... Read Full Answer >>
  3. Can mutual funds invest in options and futures? (RYMBX, GATEX)

    Mutual funds invest in not only stocks and fixed-income securities but also options and futures. There exists a separate ... Read Full Answer >>
  4. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  5. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  6. How do futures contracts roll over?

    Traders roll over futures contracts to switch from the front month contract that is close to expiration to another contract ... Read Full Answer >>
COMPANIES IN THIS ARTICLE
Trading Center